Cutia Therapeutics Expands Global Collaboration with Rejuven for Obesity-Targeted Drug CU-20401Tip Ranks·Oct 20, 2026 at 10:37 PM02487+1.54%
Weekly Recap | CUTIA-B +14.44%, board reshuffle and buyback under wayWeekly Review·Oct 3, 2026 at 05:29 AM02487+1.54%
Cutia Therapeutics Reshapes Board With CFO Exit and R&D Chief PromotionTip Ranks·Sep 30, 2026 at 08:43 AM02487+1.54%
Cutia Wins Macao Approval for Topical Finasteride, Advancing Scalp Care StrategyTip Ranks·Sep 20, 2026 at 10:37 PM02487+1.54%
HK Niche Leaders Enter Intensive Earnings and Capital Action PhaseGlobal Report·Sep 8, 2026 at 11:33 AM01086-0.37%017510.00%
Cutia Therapeutics’ Botulinum Toxin CU-20101 BLA Accepted by China’s NMPATip Ranks·Sep 2, 2026 at 10:40 PM02487+1.54%